Unknown

Dataset Information

0

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors.


ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to describe the incidence, characteristics, treatment and outcomes of CMV infection in ICI-treated patients.

Methods

We conducted a single-center retrospective review of all adult patients who were CMV-positive after ICI therapy between 06/2011 and 05/2020. A CMV-positive non-ICI cohort was matched to the ICI group based on age, sex and cancer type. Variables of interest were collected through electronic medical records.

Results

The study population comprised 192 patients overall. CMV infection incidence was 7.7% in ICI patients and 12.9% in non-ICI patients (P<0.001). Rates of infection clearance (83% vs. 50%, P=0.002) and recurrence (20% vs. 3%, P=0.037) were higher in ICI patients with hematologic vs. solid tumors, despite similar treatments. All-cause mortality was higher in solid rather than hematologic malignancies in ICI patients (83% vs. 54%, P=0.009); CMV-related mortality was low (3-4%) in both groups.

Conclusions

CMV infection occurred in about 7.7% of the ICI-treated cancer population. The infection can be disseminated in multiple organs and has a wide spectrum of clinical symptoms. ICI-treated patients with a hematologic malignancy had higher viral clearance and recurrence than those with solid tumors. In this study, CMV itself did not lead to high mortality in cancer patients. Further study is needed to investigate the role of CMV infection in patients' irAEs and cancer outcome.

SUBMITTER: Panneerselvam K 

PROVIDER: S-EPMC9399572 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors.

Panneerselvam Kavea K   Szafron David D   Amin Rajan N RN   Wei Dongguang D   Tan Dongfeng D   Altan Mehmet M   Okhuysen Pablo C PC   Shatila Malek M   Raju Gottumukkala Subba GS   Thomas Anusha S AS   Wang Yinghong Y  

Annals of gastroenterology 20220715 5


<h4>Background</h4>Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to describe the incidence, characteristics, treatment and outcomes of CMV infection in ICI-treated patients.<h4>Methods</h4>We conducted a single-center retrospective review of all adult patients  ...[more]

Similar Datasets

| S-EPMC9210781 | biostudies-literature
| S-EPMC9843387 | biostudies-literature
| S-EPMC9411835 | biostudies-literature
| S-EPMC9368813 | biostudies-literature
| S-EPMC9153254 | biostudies-literature
| S-EPMC6938975 | biostudies-literature
| S-EPMC8100539 | biostudies-literature
| S-EPMC11761211 | biostudies-literature
| S-EPMC8661141 | biostudies-literature
| S-EPMC6387531 | biostudies-literature